The opioid epidemic and corporate deception
OxyContin maker Purdue Pharma pleaded guilty to federal fraud and kickback charges. US overdose deaths fell 27% in 2024 but still claimed about 80,000 lives.
How this affects people
Aggressive marketing that downplayed addiction risks helped fuel a wave of prescription opioid use in the US, later followed by heroin and illicit fentanyl.
In 2020 Purdue Pharma pleaded guilty to three federal felonies, admitting it misled regulators and paid doctors kickbacks. Settlements now fund treatment and prevention — a documented case of corporate harm and accountability.
Look at what keeps the problem going
- 01Misleading marketing of prescription opioids
- 02Weak oversight of prescribing
- 03Illicit fentanyl supply
- 04Limited access to addiction treatment
What could happen next
The future leaves room for choices. Compare the outlooks, check what supports them and notice where the evidence becomes less certain
Declines must hold
Naloxone, treatment access and settlement funds are credited with the fall.
The future is not a timetable. These summaries reflect published scenarios and trends, with deeper uncertainty at longer horizons. Choices made now matter.
Where could a useful response begin?
Begin with a question you can investigate. Compare the sources and follow related briefings to see how the problem connects to other lives and places. This prototype does not accept proposals yet.
This preview does not accept proposals or create an account.